Cargando…

2116. Comparative Effectiveness of Amphotericin B, Azoles, and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis: A Systematic Review and Network Meta-Analysis

BACKGROUND: Current guidelines recommend the use of echinocandins, amphotericin B or fluconazole for the treatment of invasive candidiasis and candidemia. The objective of our study was to compare these agents through a systematic review of the literature and network meta-analysis of randomized cont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Demir, Koray K, Butler-Laporte, Guillaume, Lee, Todd C, Cheng, Matthew P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808766/ http://dx.doi.org/10.1093/ofid/ofz360.1796

Ejemplares similares

Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients
por: Grau, S, et al.
Publicado: (2015)

468. Assessment of The Proportion of Hospitalized Patients (Pts) with Candidemia (C) and Invasive Candidiasis without Candidemia (IC) Who Received an Echinocandin (EC) and Were Potentially Eligible for an Earlier Hospital Discharge (HD)
por: Lodise, Thomas, et al.
Publicado: (2022)

Factors associated with the development of ocular candidiasis and ocular prognosis with echinocandin therapy for candidemia
por: Sakai, Daiki, et al.
Publicado: (2021)

372. Attributable Mortality of Candidemia After Introduction of Echinocandins
por: Cornely, Florian, et al.
Publicado: (2018)

Analysis of molecular resistance to azole and echinocandin in Candida species in patients with vulvovaginal candidiasis
por: Lotfali, Ensieh, et al.
Publicado: (2022)

146 Review of Empiric Echinocandin Therapy for Candidemia
por: Amado, Cristina, et al.
Publicado: (2014)

2804. Azole versus echinocandin combination therapy for the treatment of invasive mucormycosis: A case series
por: Shah, Meera, et al.
Publicado: (2023)

Outcomes Comparing Initial Short vs Long Course Echinocandin Therapy in Patients with Candidemia Caused by Fluconazole Susceptible Strains
por: Small-Saunders, Jennifer L, et al.
Publicado: (2017)

Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B
por: Dupont, Bertrand F, et al.
Publicado: (2009)

157. A Multicenter, Mixed-Method Evaluation of Delayed Hospital Discharge in Patients with Invasive Candidiasis Receiving Echinocandins
por: Jo, Jinhee, et al.
Publicado: (2021)

Echinocandins - first line in invasive candidiasis: how strong is this 'strong' evidence?
por: Gonçalves-Pereira, João, et al.
Publicado: (2011)

Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation
por: Yeoh, Siang Fei, et al.
Publicado: (2018)

Ocular Candidiasis in Patients with Candidemia at a Large Tertiary Care Center
por: Lee, Bonny, et al.
Publicado: (2017)

635. Is Azole Prophylaxis in Liver Transplant Recipients Effective in Preventing Invasive Candidiasis in the Era of Emerging Resistance?
por: Gurram, Pooja R, et al.
Publicado: (2022)

Propranolol Ameliorates the Antifungal Activity of Azoles in Invasive Candidiasis
por: Mayandi, Venkatesh, et al.
Publicado: (2023)

2117. Fluconazole vs. Echinocandins as Initial Therapy for Candidemia Caused by Fluconazole-Susceptible Species in the Era of Rapid Diagnostic Testing
por: Roshdy, Danya, et al.
Publicado: (2019)

1702. Disseminated Candidiasis after Candidemia: Epidemiology, Diagnostic Evaluation, and Risk Factors
por: Whitehurst, Daniel, et al.
Publicado: (2023)

1173. Ocular Candidiasis in Patients with Candidemia Diagnosed by Blood Culture Versus T2Candida® Assay
por: White, Cameron, et al.
Publicado: (2020)

Decreased echinocandin susceptibility in Candida parapsilosis causing candidemia and emergence of a pan-echinocandin resistant case in China
por: Ning, Yating, et al.
Publicado: (2022)

1697. Comparison of Candidemia in Patients in Neonatal Intensive Care Unit and Pediatric Patients and Big Data Analysis on Candidiasis and Candidemia in Korean Children
por: Choi, Joon-sik, et al.
Publicado: (2019)

Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients
por: Ruhnke, M, et al.
Publicado: (2011)

2116. Impact of an Evidence-Based Intervention on Urinary Catheter Utilization in Switzerland
por: Schweiger, Alexander, et al.
Publicado: (2018)

The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards
por: De Rosa, Francesco G., et al.
Publicado: (2015)

369. Using Hybrid Models and Blockchain Technology as a Means to Develop a Novel Propensity Score for Candidemia and Invasive Candidiasis
por: Rao, Arni Sr Srinivasa, et al.
Publicado: (2018)

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Thompson, George R, et al.
Publicado: (2020)

1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study
por: Thompson, George R, et al.
Publicado: (2018)

637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Vazquez, Jose A, et al.
Publicado: (2020)

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
por: Kett, Daniel H, et al.
Publicado: (2011)

Impact of echinocandins as first-choice therapy in cardiothoracic high-risk patients with candidemia
por: Langebartels, G, et al.
Publicado: (2013)

Correction: The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards
Publicado: (2015)

Treatment of candidemia in a nationwide setting: increased survival with primary echinocandin treatment
por: Lausch, Karen Rokkedal, et al.
Publicado: (2018)

929 Comparison of Echinocandin vs Amphotericin B Based Therapy for Candida Infective Endocarditis: An Observational Cohort Study
por: Arnold, Christopher, et al.
Publicado: (2014)

149. Efficacy of Cochleated Amphotericin B (CAMB) in Mouse and Human Mucocutaneous Candidiasis
por: Desai, Jigar V, et al.
Publicado: (2020)

466. All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

370. Efficacy of Cochleated Amphotericin B (C-AMB) in Mouse Models of Oropharyngeal and Vulvovaginal Candidiasis
por: Desai, Jigar V, et al.
Publicado: (2018)

Invasive candidiasis and candidemia in pediatric and neonatal patients: A review of current guidelines
por: Vasileiou, Eleni, et al.
Publicado: (2018)

Evaluation of the Efficacy of CD101, a Novel Echinocandin, in the Treatment of Candida auris Infection Using a Murine Model of Disseminated Candidiasis
por: Hager, Christopher, et al.
Publicado: (2017)

1726. Candida albicans Virulence Genes Induced During Intra-abdominal Candidiasis (IAC) in the Absence of Antifungal Exposure Mediate Echinocandin Resistance
por: Clancy, Cornelius J, et al.
Publicado: (2019)

Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial
por: Vazquez, Jose, et al.
Publicado: (2014)

Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication
por: Vekeman, Francis, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d5370i6ajmjl3g4p23ol4rih2q